Zynerba Pharmaceuticals (ZYNE) PT Lowered to $8.50 at Roth Capital, After Study Misses Endpoints

June 30, 2020 2:15 PM

Roth Capital analyst Scott R. Henry lowered the price target on Zynerba Pharmaceuticals (NASDAQ: ZYNE) to $8.50 (from $11.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found